PhytoHealth Valuation

Is 4108 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4108 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4108's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4108's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4108?

Key metric: As 4108 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4108. This is calculated by dividing 4108's market cap by their current revenue.
What is 4108's PS Ratio?
PS Ratio	19.7x
Sales	NT$163.13m
Market Cap	NT$3.22b

4108 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	14.4x
Enterprise Value/EBITDA	-18.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 4108's PS Ratio compare to its peers?

The above table shows the PS ratio for 4108 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.4x
7754 AnnJi Pharmaceutical	17x	n/a	NT$3.1b
1762 Chunghwa Chemical Synthesis & Biotech	2x	n/a	NT$3.0b
4120 Orient EuroPharma	0.9x	n/a	NT$4.2b
8279 Syngen BiotechLtd	1.8x	n/a	NT$3.5b
4108 PhytoHealth	19.7x	n/a	NT$3.2b

Price-To-Sales vs Peers: 4108 is expensive based on its Price-To-Sales Ratio (19.7x) compared to the peer average (5.4x).

Price to Sales Ratio vs Industry

How does 4108's PS Ratio compare vs other companies in the TW Pharmaceuticals Industry?

11 Companies	Price / Sales	Estimated Growth	Market Cap
3705 YungShin Global Holding	2x	n/a	US$475.28m
1720 Standard Chemical & Pharmaceutical	1.7x	n/a	US$350.68m
3716 Cenra	0.6x	n/a	US$173.93m
1734 Sinphar PharmaceuticalLtd	1.8x	n/a	US$173.01m

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 4108 is expensive based on its Price-To-Sales Ratio (19.7x) compared to the TW Pharmaceuticals industry average (4.8x).

Price to Sales Ratio vs Fair Ratio

What is 4108's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4108 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	19.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4108's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

YungShin Global Holding

NT$15.5b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$58.10

8.6%

27.7%

RBC Bioscience

NT$258.9m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.95

-0.7%

32.1%

Cenra

NT$6.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.

1701

NT$21.15

-8.8%